A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin Equine Encephalomyelitis Virus, Eastern and Western, Equine Herpes-viruses EHV-1 and EHV-4, Equine Influenza Virus subtype A2 including KY93, KY02, and NM2/93 strains and Tetanus Toxoid. Intervet serological data suggest Influenza cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket/1/93 and Newmarket/2/93, Suffolk 89, and South Africa 03.

For vaccination of healthy horses, 6 months of age or older, as an aid in the prevention of Eastern and Western Encephalomyelitis and Tetanus, as an aid in the control of respiratory disease caused by Equine Influenza Virus and Equine Herpesvirus and as an aid in the reduction of Influenza virus shedding. Duration of Immunity (DOI) has been shown to be at least 6 months for Influenza. Foals nursing immune-dams should be vaccinated when maternal antibody levels will allow active immunization.